Other news
RTM receives marketing authorisation for Fludeoxyglucose (18F)
We are happy to announce that RTM has received marketing authorization for 18F-FDG of 17 July 2018....
First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer
The below product is manufactured at RTM First Patient Dosed in Phase II Study of TLX250-CDx in Tri...
Huntington’s Disease: A Review of the Known PET Imaging Biomarkers and Targeting Radiotracers
Klaudia Cybulska (postdoc radiochemistry) has written an article about Huntington's Disease. Abstra...
First liver cancer patient treated with microspheres irradiated in TU Delft
Radboud Translational Medicine will perform the dispensing of below product. The production and dis...
Interested in a collaboration?
Contact us to discuss the possibilities.